Filing Flows › Artivion (AORT) › Q2 2026
Artivion (AORT) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 7, 2026
Artivion (AORT) reported revenue of $126M for the second quarter 2026 (Q2 2026), +11% from a year earlier and +8% from the quarter before. Operating margin was -6.7%, net loss $13.5M (10.7% of revenue).
Artivion, Q2 2026: revenue $126M (+11% year over year), operating margin -6.7%, net loss $13.5M, operating cash flow −$1.3M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $126M | +8% | +11% |
| Operating profit | −$8.4M | -245% | -200% |
| Net earnings | −$13.5M | -1053% | -1104% |
| Operating cash flow | −$1.3M | -210% | -108% |
What changed
Revenue was $125.8M in Q2 2026, up 11% year over year and up 8% from the previous quarter. Aortic stent grafts was the largest line at 37% of revenue. Aortic stent grafts added $6.6M year over year (up 16%), 51% of the total change.
Gross margin was 64.0%, down 0.7 points from Q2 2025. Operating costs exceeded revenue by $8.4M, an operating margin of -6.7%. Operating expenses grew 37% against revenue growth of 11%. The fastest-growing cost line was SG&A (+38%). The quarter ended with a net loss of $13.5M, after a profit of $1.4M the previous quarter.
Operating cash flow was −$1.3M. Non-cash charges added back $6.7M of depreciation and amortization and $8.2M of share-based compensation. Working capital and other items used $2.7M. Capital expenditures of $10.7M exceeded it, leaving free cash flow of −$12.0M.
Questions
What was Artivion's revenue in the second quarter 2026?
Artivion (AORT) reported revenue of $126M for the second quarter 2026 (Q2 2026), +11% from a year earlier and +8% from the quarter before.
Was Artivion profitable in the second quarter 2026?
Operating loss was $8.4M (-6.7% of revenue) and net loss $13.5M.
Source: Artivion 10-Q on SEC EDGAR.